Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells.

Yoshimura K, Laird LS, Chia CY, Meckel KF, Slansky JE, Thompson JM, Jain A, Pardoll DM, Schulick RD.

Cancer Res. 2007 Oct 15;67(20):10058-66.

2.

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD.

Cancer Res. 2006 Jan 15;66(2):1096-104.

3.

Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.

Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y.

Oncol Rep. 2009 Aug;22(2):337-43.

PMID:
19578774
4.

Attenuated Listeria infection activates natural killer cell cytotoxicity to regress melanoma growth in vivo.

Shen H, Kanoh M, Maruyama S, Matsumoto A, Zhang W, Asano Y.

Microbiol Immunol. 2008 Feb;52(2):107-17. doi: 10.1111/j.1348-0421.2008.00018.x.

5.

Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma.

Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, Frankel FR, Sun B.

Oncogene. 2012 Apr 26;31(17):2140-52. doi: 10.1038/onc.2011.395. Epub 2011 Sep 19. Erratum in: Oncogene. 2012 Nov 8;31(45):4810.

PMID:
21927025
6.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

7.

Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent?

Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM.

J Pediatr Surg. 1997 Feb;32(2):301-6.

PMID:
9044141
8.

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA.

Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.

9.

Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.

Lee CH, Chiang YH, Chang SE, Chong CL, Cheng BM, Roffler SR.

Clin Cancer Res. 2009 Apr 15;15(8):2756-66. doi: 10.1158/1078-0432.CCR-08-2311. Epub 2009 Mar 24.

10.

Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases.

Olino K, Wada S, Edil BH, Pan X, Meckel K, Weber W, Slansky J, Tamada K, Lauer P, Brockstedt D, Pardoll D, Schulick R, Yoshimura K.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S597-607. doi: 10.1245/s10434-011-2037-0. Epub 2011 Oct 7.

11.

Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.

Khamisabadi M, Arab S, Motamedi M, Khansari N, Moazzeni SM, Gheflati Z, Hadjati J.

Iran J Immunol. 2008 Mar;5(1):36-44. doi: IJIv5i1A3.

PMID:
18319523
12.

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.

Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A.

Cancer Gene Ther. 2011 Jan;18(1):53-62. doi: 10.1038/cgt.2010.48. Epub 2010 Aug 20.

PMID:
20725099
13.

DC therapy induces long-term NK reactivity to tumors via host DC.

Shimizu K, Fujii S.

Eur J Immunol. 2009 Feb;39(2):457-68. doi: 10.1002/eji.200838794.

14.

Development of a Listeria monocytogenes based vaccine against prostate cancer.

Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P.

Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. doi: 10.1007/s00262-008-0463-z. Epub 2008 Feb 14.

PMID:
18273616
15.

Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer.

Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Beckhove P, Weitz J.

Ann Surg Oncol. 2008 Aug;15(8):2310-7. doi: 10.1245/s10434-008-9971-5. Epub 2008 Jun 3. Erratum in: Ann Surg Oncol. 2009 Apr;16(4):1084. Rahbari, Nuh [added].

PMID:
18521684
16.

Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.

Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH.

Ann Surg Oncol. 2009 May;16(5):1403-11. doi: 10.1245/s10434-009-0343-6. Epub 2009 Mar 5.

PMID:
19263173
17.

Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.

Pilla L, Squarcina P, Coppa J, Mazzaferro V, Huber V, Pende D, Maccalli C, Sovena G, Mariani L, Castelli C, Parmiani G, Rivoltini L.

Cancer Res. 2005 May 1;65(9):3942-9.

18.

Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy.

Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolò C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F.

J Immunol. 2010 Jun 1;184(11):6124-32. doi: 10.4049/jimmunol.0901215. Epub 2010 Apr 30.

19.

IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.

Moreno M, Molling JW, von Mensdorff-Pouilly S, Verheijen RH, Hooijberg E, Kramer D, Reurs AW, van den Eertwegh AJ, von Blomberg BM, Scheper RJ, Bontkes HJ.

J Immunol. 2008 Aug 15;181(4):2446-54.

20.

Stimulation of enhanced CD8 T cell responses following immunization with a hyper-antigen secreting intracytosolic bacterial pathogen.

Smithey MJ, Brandt S, Freitag NE, Higgins DE, Bouwer HG.

J Immunol. 2008 Mar 1;180(5):3406-16.

Supplemental Content

Support Center